Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Helicobacter Pylori | Research article

Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma

Authors: Yuan Cheng, Yinan Xiao, Ruofan Zhou, Yi Liao, Jing Zhou, Xuelei Ma

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Helicobacter pylori (H. pylori) is thought to have an oncogenic effect on the development of gastric malignancies. However, the effect of H. pylori status on the prognosis of gastric diffuse large B-cell lymphoma (DLBCL) remains unconfirmed. This study aimed to identify the prognostic importance of H. pylori infection in de novo gastric DLBCL.

Methods

One hundred and twenty-nine patients diagnosed with primary de novo gastric DLBCL at the West China Hospital of Sichuan University from 1st January 2009 to 31st May 2016 were included. The clinical features of the patients were documented. H. pylori status was assessed via urease breath tests and histologic examinations. The prognostic value of H. pylori was verified via univariate and multivariate analyses.

Results

Over a median follow-up of 52.2 months (range 4–116), the 5-year overall survival (OS) for all patients was 78.7%. Patients with H. pylori infections had significantly better 5-year PFS and OS than did the H. pylori-negative subgroup (5-year PFS, 89.3% vs. 74.1%, P = 0.040; 5-year OS, 89.7% vs. 71.8%, P = 0.033). Negative H. pylori status and poor ECOG performance were independent negative prognostic indicators for both PFS and OS (PFS, P = 0.045 and P = 0.001, respectively; OS, P = 0.021 and P < 0.001, respectively).

Conclusions

H. pylori status in de novo gastric DLBCL can be a promising predictor of disease outcome, and patients with negative H. pylori status require careful follow-up since they tend to have a worse outlook.
Literature
1.
go back to reference Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7.PubMed Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7.PubMed
2.
go back to reference Tondini C, Giardini R, Bozzetti F, et al. Combined modality treatment for primary gastrointestinal non-Hodgkin’s lymphoma: the Milan Cancer institute experience. Ann Oncol. 1993;4:831–7.CrossRefPubMed Tondini C, Giardini R, Bozzetti F, et al. Combined modality treatment for primary gastrointestinal non-Hodgkin’s lymphoma: the Milan Cancer institute experience. Ann Oncol. 1993;4:831–7.CrossRefPubMed
3.
go back to reference Howell JM, Auer-Grzesiak I, Zhang J, et al. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012;26:452–6.CrossRefPubMedPubMedCentral Howell JM, Auer-Grzesiak I, Zhang J, et al. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012;26:452–6.CrossRefPubMedPubMedCentral
4.
5.
go back to reference Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–9.CrossRefPubMedPubMedCentral Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–9.CrossRefPubMedPubMedCentral
6.
go back to reference Hatakeyama M. Oncogenic mechanisms of the helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4:688–94.CrossRefPubMed Hatakeyama M. Oncogenic mechanisms of the helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4:688–94.CrossRefPubMed
7.
go back to reference Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
8.
go back to reference Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175–6.CrossRefPubMed Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175–6.CrossRefPubMed
9.
go back to reference Amieva M, Peek RM. Pathobiology of helicobacter pylori-induced gastric Cancer. Gastroenterology. 2016;150:64–78.CrossRefPubMed Amieva M, Peek RM. Pathobiology of helicobacter pylori-induced gastric Cancer. Gastroenterology. 2016;150:64–78.CrossRefPubMed
10.
go back to reference Suzuki T, Matsuo K, Ito H, et al. A past history of gastric ulcers and helicobacter pylori infection increase the risk of gastric malignant lymphoma. Carcinogenesis. 2006;27:1391–7.CrossRefPubMed Suzuki T, Matsuo K, Ito H, et al. A past history of gastric ulcers and helicobacter pylori infection increase the risk of gastric malignant lymphoma. Carcinogenesis. 2006;27:1391–7.CrossRefPubMed
11.
go back to reference Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–22.CrossRefPubMed Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–22.CrossRefPubMed
12.
go back to reference Marrelli D, Pedrazzani C, Berardi A, et al. Negative helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115:2071–80.CrossRefPubMed Marrelli D, Pedrazzani C, Berardi A, et al. Negative helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009;115:2071–80.CrossRefPubMed
13.
go back to reference Postlewait LM, Squires MH, Kooby DA, et al. Preoperative helicobacter pylori infection is associated with increased survival after resection of gastric adenocarcinoma. Ann Surg Oncol. 2016;23:1225–33.CrossRefPubMed Postlewait LM, Squires MH, Kooby DA, et al. Preoperative helicobacter pylori infection is associated with increased survival after resection of gastric adenocarcinoma. Ann Surg Oncol. 2016;23:1225–33.CrossRefPubMed
14.
go back to reference Hussell T, Isaacson PG, Crabtree JE, et al. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to helicobacter pylori. Lancet. 1993;342:571–4.CrossRefPubMed Hussell T, Isaacson PG, Crabtree JE, et al. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to helicobacter pylori. Lancet. 1993;342:571–4.CrossRefPubMed
15.
go back to reference Neubauer A, Thiede C, Morgner A, et al. Cure of helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350–5.CrossRefPubMed Neubauer A, Thiede C, Morgner A, et al. Cure of helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350–5.CrossRefPubMed
16.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
17.
go back to reference Chen LT, Lin JT, Shyu RY, et al. Prospective study of helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245–51.CrossRefPubMed Chen LT, Lin JT, Shyu RY, et al. Prospective study of helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245–51.CrossRefPubMed
18.
go back to reference Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of helicobacter pylori infection. J Clin Oncol. 2001;19:2041–8.CrossRefPubMed Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of helicobacter pylori infection. J Clin Oncol. 2001;19:2041–8.CrossRefPubMed
19.
go back to reference Kuo SH, Yeh KH, Chen LT, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:e220.CrossRefPubMedPubMedCentral Kuo SH, Yeh KH, Chen LT, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:e220.CrossRefPubMedPubMedCentral
20.
go back to reference Huang WT, Kuo SH, Cheng AL, et al. Inhibition of ZEB1 by miR-200 characterizes helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. Mod Pathol. 2014;27:1116–25.CrossRefPubMed Huang WT, Kuo SH, Cheng AL, et al. Inhibition of ZEB1 by miR-200 characterizes helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. Mod Pathol. 2014;27:1116–25.CrossRefPubMed
21.
go back to reference Chan JK, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol. 1990;136:1153–64.PubMedPubMedCentral Chan JK, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol. 1990;136:1153–64.PubMedPubMedCentral
22.
go back to reference de Jong D, Boot H, van Heerde P, et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology. 1997;112:1466–74.CrossRefPubMed de Jong D, Boot H, van Heerde P, et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology. 1997;112:1466–74.CrossRefPubMed
23.
go back to reference Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.CrossRefPubMed Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.CrossRefPubMed
24.
go back to reference Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.CrossRefPubMed Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.CrossRefPubMed
25.
go back to reference Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007;56:1685–7.CrossRefPubMedPubMedCentral Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007;56:1685–7.CrossRefPubMedPubMedCentral
26.
go back to reference Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–53.CrossRefPubMed Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–53.CrossRefPubMed
27.
go back to reference Sugimoto M, Kajimura M, Sato Y, et al. Regression of primary gastric diffuse large B-cell lymphoma after eradication of helicobacter pylori. Gastrointest Endosc. 2001;54:643–5.CrossRefPubMed Sugimoto M, Kajimura M, Sato Y, et al. Regression of primary gastric diffuse large B-cell lymphoma after eradication of helicobacter pylori. Gastrointest Endosc. 2001;54:643–5.CrossRefPubMed
28.
go back to reference Alsolaiman MM, Bakis G, Nazeer T, et al. Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of helicobacter pylori infection. Gut. 2003;52:507–9.CrossRefPubMedPubMedCentral Alsolaiman MM, Bakis G, Nazeer T, et al. Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of helicobacter pylori infection. Gut. 2003;52:507–9.CrossRefPubMedPubMedCentral
29.
go back to reference Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838–44 quiz 5057.CrossRefPubMed Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838–44 quiz 5057.CrossRefPubMed
30.
go back to reference Murata-Kamiya N, Kikuchi K, Hayashi T, et al. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell Host Microbe. 2010;7:399–411.CrossRefPubMed Murata-Kamiya N, Kikuchi K, Hayashi T, et al. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell Host Microbe. 2010;7:399–411.CrossRefPubMed
31.
go back to reference Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996;111:655–65.CrossRefPubMed Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996;111:655–65.CrossRefPubMed
32.
go back to reference Xue LJ, Su QS, Yang JH, et al. Autoimmune responses induced by helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses. 2008;70:273–6.CrossRefPubMed Xue LJ, Su QS, Yang JH, et al. Autoimmune responses induced by helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses. 2008;70:273–6.CrossRefPubMed
33.
go back to reference Kuo SH, Chen LT, Lin CW, et al. Detection of the helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance. Blood Cancer J. 2013;3:e125.CrossRefPubMedPubMedCentral Kuo SH, Chen LT, Lin CW, et al. Detection of the helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance. Blood Cancer J. 2013;3:e125.CrossRefPubMedPubMedCentral
34.
go back to reference Lemma S, Karihtala P, Haapasaari KM, et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors twist, ZEB1 and slug in diffuse large B-cell lymphoma. Histopathology. 2013;62:326–33.CrossRefPubMed Lemma S, Karihtala P, Haapasaari KM, et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors twist, ZEB1 and slug in diffuse large B-cell lymphoma. Histopathology. 2013;62:326–33.CrossRefPubMed
Metadata
Title
Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma
Authors
Yuan Cheng
Yinan Xiao
Ruofan Zhou
Yi Liao
Jing Zhou
Xuelei Ma
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6067-5

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine